Efficacy and safety of elagolix with add-back therapy in women with uterine fibroids and coexisting adenomyosis

OBJECTIVE: To determine if coexisting adenomyosis limits the efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy in reducing heavy menstrual bleeding in women with uterine fibroids. DESIGN: Pooled analysis of two identical, double-blind, randomized...

Descripción completa

Detalles Bibliográficos
Autores principales: Muneyyirci-Delale, Ozgul, Archer, David F., Owens, Charlotte D., Barnhart, Kurt T., Bradley, Linda D., Feinberg, Eve, Gillispie, Veronica, Hurtado, Sandra, Kim, Jin Hee, Wang, Alice, Wang, Hui, Stewart, Elizabeth A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441572/
https://www.ncbi.nlm.nih.gov/pubmed/34553161
http://dx.doi.org/10.1016/j.xfre.2021.05.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8441572/
https://www.ncbi.nlm.nih.gov/pubmed/34553161
http://dx.doi.org/10.1016/j.xfre.2021.05.004

Ejemplares similares